TCRX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TCRX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. TScan Therapeutics's Degree of Operating Leverage for the quarter that ended in Sep. 2024 was -0.86. The higher Degree of Operating Leverage, the higher operating risk the company will take.
The industry rank for TScan Therapeutics's Degree of Operating Leverage or its related term are showing as below:
The historical data trend for TScan Therapeutics's Degree of Operating Leverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TScan Therapeutics Annual Data | |||||||||||
Trend | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||
Degree of Operating Leverage | - | - | 0.10 | 1.01 | 1.18 |
TScan Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Degree of Operating Leverage | Get a 7-Day Free Trial | -329.91 | 1.18 | 3.48 | -5.97 | -0.86 |
For the Biotechnology subindustry, TScan Therapeutics's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Degree of Operating Leverage distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's Degree of Operating Leverage falls into.
TScan Therapeutics's Degree of Operating Leverage for the quarter that ended in Sep. 2024 is calculated as:
Degree of Operating Leverage | = | % Change in EBIT** | / | % Change in Revenue |
= | ( -107.582 (Sep. 2024) / -85.915 (Sep. 2023) - 1 ) | / | ( 9.362 (Sep. 2024) / 13.278 (Sep. 2023) - 1 ) | |
= | 0.2522 | / | -0.2949 | |
= | -0.86*** |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
TScan Therapeutics (NAS:TCRX) Degree of Operating Leverage Explanation
Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.
A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.
Be Aware
The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.
Thank you for viewing the detailed overview of TScan Therapeutics's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.
Lynx1 Capital Management Lp | 10 percent owner | 151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607 |
Barbara Klencke | director | C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404 |
Zoran Zdraveski | officer: Chief Legal Officer | C/O MAGENTA THERAPEUTICS, 50 HAMPSHIRE STREET, CAMBRIDGE MA 02139 |
Timothy J Barberich | director | 40 ELM ST, CONCORD MA 01752 |
Leiden Dworak | officer: Chief Accounting Officer | C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451 |
Weston Nichols | 10 percent owner | C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121 |
Ecor1 Capital, Llc | 10 percent owner | 357 TEHAMA STREET #3, SAN FRANCISCO CA 94103 |
Brian M. Silver | officer: Chief Financial Officer | C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
Debora Barton | officer: Chief Medical Officer | C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451 |
David P Southwell | director, officer: Chief Executive Officer | C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421 |
Baker Bros. Advisors Lp | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Julian Baker | director, 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Baker Brothers Life Sciences Lp | director, 10 percent owner | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Felix Baker | director, 10 percent owner | BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014 |
From GuruFocus
By Marketwired • 04-24-2024
By GuruFocus News • 11-15-2024
By GlobeNewswire • 04-22-2024
By Marketwired • 05-30-2024
By Marketwired • 04-16-2024
By GuruFocus News • 11-20-2024
By Marketwired • 04-17-2024
By Marketwired • 04-19-2024
By GuruFocus Research • 08-14-2024
By GuruFocus Research • 03-07-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.